|
1
|
Knight DM, Trinh H, Le J, Siegel S, Shealy
D, McDonough M, Scallon B, Moore MA, Vilcek J, Daddona P, et al:
Construction and initial characterization of a mouse-human chimeric
anti-TNF antibody. Mol Immunol. 30:1443–1453. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Scallon BJ, Moore MA, Trinh H, Knight DM
and Ghrayeb J: Chimeric anti-TNF-alpha monoclonal antibody cA2
binds recombinant transmembrane TNF-alpha and activates immune
effector functions. Cytokine. 7:251–259. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Van Deventer SJ: Tumour necrosis factor
and Crohn's disease. Gut. 40:443–448. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Feldmann M, Brennan FM and Maini RN:
Rheumatoid arthritis. Cell. 85:307–310. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Guignard S, Gossec L, Salliot C,
Ruyssen-Witrand A, Luc M, Duclos M and Dougados M: Efficacy of
tumour necrosis factor blockers in reducing uveitis flares in
patients with spondylarthropathy: A retrospective study. Ann Rheum
Dis. 65:1631–1634. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Murch SH, Braegger CP, Walker-Smith JA and
MacDonald TT: Location of tumour necrosis factor alpha by
immunohistochemistry in chronic inflammatory bowel disease. Gut.
34:1705–1709. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Husby G and Williams RC Jr: Synovial
localization of tumor necrosis factor in patients with rheumatoid
arthritis. J Autoimmun. 1:363–371. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tse SM, Burgos-Vargas R and Laxer RM:
Anti-tumor necrosis factor alpha blockade in the treatment of
juvenile spondylarthropathy. Arthritis Rheum. 52:2103–2108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Aaltonen KJ, Virkki LM, Malmivaara A,
Konttinen YT, Nordström DC and Blom M: Systematic review and
meta-analysis of the efficacy and safety of existing TNF blocking
agents in treatment of rheumatoid arthritis. PLoS One.
7:e302752012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wiens A, Correr CJ, Venson R, Grochocki
MC, Otuki MF and Pontarolo R: A meta-analysis of the efficacy and
safety of using infliximab for the treatment of rheumatoid
arthritis. Clin Rheumatol. 28:1365–1373. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wiens A, Venson R, Correr CJ, Otuki MF and
Pontarolo R: Meta-analysis of the efficacy and safety of
adalimumab, etanercept and infliximab for the treatment of
rheumatoid arthritis. Pharmacotherapy. 30:339–353. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Stidham RW, Lee TC, Higgins PD, Deshpande
AR, Sussman DA, Singal AG, Elmunzer BJ, Saini SD, Vijan S and
Waljee AK: Systematic review with network meta-analysis: The
efficacy of anti-tumour necrosis factor-alpha agents for the
treatment of ulcerative colitis. Aliment Pharmacol Ther.
39:660–671. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Scheinfeld N: A comprehensive review and
evaluation of the side effects of the tumor necrosis factor alpha
blockers etanercept, infliximab and adalimumab. J Dermatolog Treat.
15:280–294. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Flynn JL, Goldstein MM, Chan J, Triebold
KJ, Pfeffer K, Lowenstein CJ, Schreiber R, Mak TW and Bloom BR:
Tumor necrosis factor-alpha is required in the protective immune
response against Mycobacterium tuberculosis in mice. Immunity.
2:561–572. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kindler V, Sappino AP, Grau GE, Piguet PF
and Vassalli P: The inducing role of tumor necrosis factor in the
development of bactericidal granulomas during BCG infection. Cell.
56:731–740. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mohan VP, Scanga CA, Yu K, Scott HM,
Tanaka KE, Tsang E, Tsai MM, Flynn JL and Chan J: Effects of tumor
necrosis factor alpha on host immune response in chronic persistent
tuberculosis: Possible role for limiting pathology. Infect Immun.
69:1847–1855. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ford AC and Peyrin-Biroulet L:
Opportunistic infections with anti-tumor necrosis factor-alpha
therapy in inflammatory bowel disease: Meta-analysis of randomized
controlled trials. Am J Gastroenterol. 108:1268–1276. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Keane J, Gershon S, Wise RP,
Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN and Braun
MM: Tuberculosis associated with infliximab, a tumor necrosis
factor alpha-neutralizing agent. N Engl J Med. 345:1098–1104. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wallis RS, Broder MS, Wong JY, Hanson ME
and Beenhouwer DO: Granulomatous infectious diseases associated
with tumor necrosis factor antagonists. Clin Infect Dis.
38:1261–1265. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Askling J, Fored CM, Brandt L, Baecklund
E, Bertilsson L, Cöster L, Geborek P, Jacobsson LT, Lindblad S,
Lysholm J, et al: Risk and case characteristics of tuberculosis in
rheumatoid arthritis associated with tumor necrosis factor
antagonists in Sweden. Arthritis Rheum. 52:1986–1992. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Moher D, Liberati A, Tetzlaff J and Altman
DG: PRISMA Group: Preferred reporting items for systematic reviews
and meta-analyses: The PRISMA statement. PLoS Med. 6:e10000972009.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jadad AR, Moore RA, Carroll D, Jenkinson
C, Reynolds DJ, Gavaghan DJ and McQuay HJ: Assessing the quality of
reports of randomized clinical trials: Is blinding necessary?
Control Clin Trials. 17:1–12. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Moher D, Pham B, Jones A, Cook DJ, Jadad
AR, Moher M, Tugwell P and Klassen TP: Does quality of reports of
randomised trials affect estimates of intervention efficacy
reported in meta-analyses? Lancet. 352:609–613. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Targan SR, Hanauer SB, van Deventer SJ,
Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF and
Rutgeerts PJ: A short-term study of chimeric monoclonal antibody
cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's
Disease cA2 Study Group. N Engl J Med. 337:1029–1035. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Present DH, Rutgeerts P, Targan S, Hanauer
SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T,
DeWoody KL, et al: Infliximab for the treatment of fistulas in
patients with Crohn's disease. N Engl J Med. 340:1398–1405. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sands BE, Tremaine WJ, Sandborn WJ,
Rutgeerts PJ, Hanauer SB, Mayer L, Targan SR and Podolsky DK:
Infliximab in the treatment of severe, steroid-refractory
ulcerative colitis: A pilot study. Inflamm Bowel Dis. 7:83–88.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hanauer SB, Feagan BG, Lichtenstein GR,
Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson
A, Bao W, et al: ACCENT I Study Group: Maintenance infliximab for
Crohn's disease: The ACCENT I randomised trial. Lancet.
359:1541–1549. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sands BE, Anderson FH, Bernstein CN, Chey
WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken
JE, et al: Infliximab maintenance therapy for fistulizing Crohn's
disease. N Engl J Med. 350:876–885. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rutgeerts P, Sandborn WJ, Feagan BG,
Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer
SB, Lichtenstein GR, et al: Infliximab for induction and
maintenance therapy for ulcerative colitis. N Engl J Med.
353:2462–2476. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lemann M, Mary JY, Duclos B, Veyrac M,
Dupas JL, Delchier JC, Laharie D, Moreau J, Cadiot G, Picon L, et
al: Infliximab plus azathioprine for steroid-dependent Crohn's
disease patients: A randomized placebo-controlled trial.
Gastroenterology. 130:1054–1061. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Colombel JF, Sandborn WJ, Reinisch W,
Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens G,
Diamond RH, Broussard DL, et al: Infliximab, azathioprine, or
combination therapy for Crohn's disease. N Engl J Med.
362:1383–1395. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ochsenkuhn T, Sackmann M and Göke B:
Infliximab for acute, not steroid-refractory ulcerative colitis: A
randomized pilot study. Eur J Gastroenterol Hepatol. 16:1167–1171.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Maini RN, Breedveld FC, Kalden JR, Smolen
JS, Davis D, Macfarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN,
et al: Therapeutic efficacy of multiple intravenous infusions of
anti-tumor necrosis factor alpha monoclonal antibody combined with
low-dose weekly methotrexate in rheumatoid arthritis. Arthritis
Rheum. 41:1552–1563. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lipsky PE, van der Heijde DM, St Clair EW,
Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P,
Feldmann M, et al: Infliximab and methotrexate in the treatment of
rheumatoid arthritis. Anti-tumor necrosis factor trial in
rheumatoid arthritis with concomitant therapy study group. N Engl J
Med. 343:1594–1602. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
St Clair EW, van der Heijde DM, Smolen JS,
Maini RN, Bathon JM, Emery P, Keystone E, Schiff M, Kalden JR, Wang
B, et al: Active-Controlled Study of Patients Receiving Infliximab
for the Treatment of Rheumatoid Arthritis of Early Onset Study
Group: Combination of infliximab and methotrexate therapy for early
rheumatoid arthritis: A randomized, controlled trial. Arthritis
Rheum. 50:3432–3443. 2004. View Article : Google Scholar
|
|
36
|
Quinn MA, Conaghan PG, O'Connor PJ, Karim
Z, Greenstein A, Brown A, Brown C, Fraser A, Jarret S and Emery P:
Very early treatment with infliximab in addition to methotrexate in
early, poor-prognosis rheumatoid arthritis reduces magnetic
resonance imaging evidence of synovitis and damage, with sustained
benefit after infliximab withdrawal: Results from a twelve-month
randomized, double-blind, placebo-controlled trial. Arthritis
Rheum. 52:27–35. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Westhovens R, Yocum D, Han J, Berman A,
Strusberg I, Geusens P and Rahman MU: START Study Group: The safety
of infliximab, combined with background treatments, among patients
with rheumatoid arthritis and various comorbidities: A large,
randomized, placebo-controlled trial. Arthritis Rheum.
54:1075–1086. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Abe T, Takeuchi T, Miyasaka N, Hashimoto
H, Kondo H, Ichikawa Y and Nagaya I: A multicenter, double-blind,
randomized, placebo controlled trial of infliximab combined with
low dose methotrexate in Japanese patients with rheumatoid
arthritis. J Rheumatol. 33:37–44. 2006.PubMed/NCBI
|
|
39
|
Schiff M, Keiserman M, Codding C,
Songcharoen S, Berman A, Nayiager S, Saldate C, Li T, Aranda R,
Becker JC, et al: Efficacy and safety of abatacept or infliximab vs
placebo in ATTEST: A phase III, multi-centre, randomised,
double-blind, placebo-controlled study in patients with rheumatoid
arthritis and an inadequate response to methotrexate. Ann Rheum
Dis. 67:1096–1103. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Braun J, Brandt J, Listing J, Zink A,
Alten R, Golder W, Gromnica-Ihle E, Kellner H, Krause A, Schneider
M, et al: Treatment of active ankylosing spondylitis with
infliximab: A randomised controlled multicentre trial. Lancet.
359:1187–1193. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
van der Heijde D, Dijkmans B, Geusens P,
Sieper J, DeWoody K, Williamson P and Braun J: Ankylosing
Spondylitis Study for the Evaluation of Recombinant Infliximab
Therapy Study Group: Efficacy and safety of infliximab in patients
with ankylosing spondylitis: Results of a randomized,
placebo-controlled trial (ASSERT). Arthritis Rheum. 52:582–591.
2005. View Article : Google Scholar
|
|
42
|
Marzo-Ortega H, McGonagle D, Jarrett S,
Haugeberg G, Hensor E, O'connor P, Tan AL, Conaghan PG, Greenstein
A and Emery P: Infliximab in combination with methotrexate in
active ankylosing spondylitis: A clinical and imaging study. Ann
Rheum Dis. 64:1568–1575. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Inman RD and Maksymowych WP: CANDLE Study
Group: Adouble-blind, placebo-controlled trial of low dose
infliximab in ankylosing spondylitis. J Rheumatol. 37:1203–1210.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Van den Bosch F, Kruithof E, Baeten D,
Herssens A, de Keyser F, Mielants H and Veys EM: Randomized
double-blind comparison of chimeric monoclonal antibody to tumor
necrosis factor alpha (infliximab) versus placebo in active
spondylarthropathy. Arthritis Rheum. 46:755–765. 2002. View Article : Google Scholar
|
|
45
|
Antoni C, Krueger GG, de Vlam K, Birbara
C, Beutler A, Guzzo C, Zhou B, Dooley LT and Kavanaugh A: IMPACT 2
Trial Investigators: Infliximab improves signs and symptoms of
psoriatic arthritis: Results of the IMPACT 2 trial. Ann Rheum Dis.
64:1150–1157. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kavanaugh A, Krueger GG, Beutler A, Guzzo
C, Zhou B, Dooley LT, Mease PJ, Gladman DD, de Vlam K, Geusens PP,
et al: Infliximab maintains a high degree of clinical response in
patients with active psoriatic arthritis through 1 year of
treatment: Results from the IMPACT 2 trial. Ann Rheum Dis.
66:498–505. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Sieper J, Lenaerts J, Wollenhaupt J,
Rudwaleit M, Mazurov VI, Myasoutova L, Park S, Song Y, Yao R,
Chitkara D, et al: Efficacy and safety of infliximab plus naproxen
vs. naproxen alone in patients with early, active axial
spondyloarthritis: Results from the double-blind,
placebo-controlled INFAST study, Part 1. Ann Rheum Dis. 73:101–107.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Algood HM, Lin PL and Flynn JL: Tumor
necrosis factor and chemokine interactions in the formation and
maintenance of granulomas in tuberculosis. Clin Infect Dis.
41(Suppl 3): S189–S193. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
49
|
White DW and Harty JT: Perforin-deficient
CD8+ T cells provide immunity to Listeria monocytogenes
by a mechanism that is independent of CD95 and IFN-gamma but
requires TNF-alpha. J Immunol. 160:898–905. 1998.PubMed/NCBI
|
|
50
|
Zhou P, Miller G and Seder RA: Factors
involved in regulating primary and secondary immunity to infection
with Histoplasma capsulatum: TNF-alpha plays a critical role in
maintaining secondary immunity in the absence of IFN-gamma. J
Immunol. 160:1359–1368. 1998.PubMed/NCBI
|
|
51
|
Roach DR, Bean AG, Demangel C, France MP,
Briscoe H and Britton WJ: TNF regulates chemokine induction
essential for cell recruitment, granuloma formation, and clearance
of mycobacterial infection. J Immunol. 168:4620–4627. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zumla A, George A, Sharma V, Herbert N and
Baroness Masham: of Ilton: WHO's 2013 global report on
tuberculosis: Successes, threats, and opportunities. Lancet.
382:1765–1767. 2013. View Article : Google Scholar : PubMed/NCBI
|
